In 2023, nearly 1 in 4 US adults were living with chronic pain, and 8.5% experienced pain severe enough to limit daily life ...

People living with cystic fibrosis can now take a once-daily drug that will help them breathe easier all day long, thanks to ...

The listening room with a bespoke sound system reflecting Alessandro Michele's vision was conceived in partnership with ...

The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their research efforts around the adeno-associated virus (AAV) vectors used ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

Vertex Pharmaceuticals saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal challenges ...

The deal has been announced just a few days after the FDA lifted a clinical hold on a phase 1/2 trial of VX-880 – a stem cell therapy Vertex acquired through its near $1 billion acquisition of ...

EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...